Enrollment continues in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 studies of MDMA-assisted therapy for the treatment of PTSD.
You are eligible to participate in this study if you completed participation in our MP16, MP17, MAPP1, MAPP2, or MAPPUSX studies at least 6 months ago. This long-term follow up study is conducted remotely. If you have not yet participated and would like to, please reach out to the study team at mapsfollowup@ucsf.edu.
